Pharmaceutical industry
At the upcoming 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), Genentech, a leading biotechnology company, will present new data on its targeted cancer medicines that may be used in several different cancer types. The meeting, taking place June 4 to 8 in Chicago, will feature approximately
Pharmaceutical industry
The global H1N1 vaccines market experienced significant growth in 2009 and 2010 due to the pandemic outbreak. The market was driven by government initiatives to develop and distribute vaccines, as well as increased demand for infection prevention and control measures. Major companies such as Baxter International, Novartis, and Sanofi Pasteur
Pharmaceutical industry
The global market for liver cancer drugs is expected to grow steadily over the next several years, driven by increasing demand for targeted therapies and improved diagnostic techniques. Liver cancer, also known as hepatic cancer, is a type of cancer that begins in the liver's cells. It is
Pharmaceutical industry
Justin Adendorff, a five-year veteran of the company, has been promoted to vice president at Barrier Advisors, a nationally recognized middle-market restructuring, operations improvement, and special situations investment banking firm. Adendorff has extensive experience in various industries, including pharmaceuticals, biotechnology, healthcare, entertainment, industrial machinery, energy, utilities, and packaging. He has
Pharmaceutical industry
Human Genome Sciences, Inc. and GlaxoSmithKline PLC announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). BENLYSTA 10 mg/kg already met its primary efficacy endpoint at Week 52 in both BLISS-52 and BLISS-76,
Pharmaceutical industry
Oncolytics Biotech Inc., a Calgary-based biotechnology company, has announced the initiation of a U.S. Phase 2 clinical trial using its proprietary formulation of the human reovirus, REOLYSIN, in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs. The trial, led by Dr. Alain C.
Pharmaceutical industry
TRACON Pharmaceuticals, a biotechnology company focused on developing targeted therapies, has announced that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer. This trial marks a significant step forward in the development of TRC105, a monoclonal antibody that
Pharmaceutical industry
The biotech sector was marked by a mixed performance on this particular day, with several top biotech companies experiencing significant price movements due to earnings and other news. Antigenics Inc. led the charge with a 3.4% gain, followed closely by Array BioPharma, Inc. which held up well despite a
Pharmaceutical industry
Human Genome Sciences Inc. (HGSI) recently encountered a setback in the development of its hepatitis C candidate Joulferon (albinterferon alfa-2b) after its partner Novartis AG (NVS) withdrew the Marketing Authorization Application (MAA) from the European Medicines Agency (EMEA). This move was due to indications that the European regulatory authorities would
Pharmaceutical industry
The US Food and Drug Administration (FDA) granted clearance to Vasomedical's Combined ECG Holter and Ambulatory Blood Pressure Monitoring System, while Cell Therapeutics received a Complete Response Letter for its Pixuvri NDA. Meanwhile, Ardea Biosciences completed a public offering of common stock, raising approximately $77.1 million, and
Pharmaceutical industry
Developments in pharmaceutical research and biotechnology hold promise for the black community, addressing high rates of asthma, diabetes, sickle cell anemia, and cancer. New medicines in development target specific health issues that disproportionately affect African Americans. With higher asthma rates and a higher likelihood of death from the disease, a
Pharmaceutical industry
Takeda Pharmaceutical Co. has initiated Phase III clinical trials in the U.S., Europe, and Russia for a lymphoma treatment, marking a significant step in the development of SGN-35. This conjugate drug, developed jointly with Seattle Genetics Inc., aims to combine an anti-cancer agent with an antibody targeting an antigen
